Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250

NCT00602862 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG: Sorafenib
DRUG: 111Indium-bevacizumab
DRUG: 111Indium-cG250

Sponsor

Radboud University Medical Center

Collaborators

[object Object]